| Identification | Back Directory | [Name]
LY288513 | [CAS]
147523-65-7 | [Synonyms]
LY288513
(4S,5R)-N-(4-Bromophenyl)-3-oxo-4,5-diphenyl-1-pyrazolidinecarboxamide
1-Pyrazolidinecarboxamide, N-(4-bromophenyl)-3-oxo-4,5-diphenyl-, (4S,5R)- | [Molecular Formula]
C22H18BrN3O2 | [MOL File]
147523-65-7.mol | [Molecular Weight]
436.3 |
| Chemical Properties | Back Directory | [Melting point ]
120-122°C | [storage temp. ]
Store at +4°C | [solubility ]
DMSO (Slightly), Methanol (Very Slightly) | [form ]
Solid | [color ]
White |
| Hazard Information | Back Directory | [Uses]
LY 288513 is a CCK-B antagonist, which blocks the effects of nicotine withdrawal on auditory startle. | [Definition]
ChEBI:(4S,5R)-N-(4-bromophenyl)-3-oxo-4,5-diphenyl-1-pyrazolidinecarboxamide is a stilbenoid. | [Biological Activity]
Selective CCK 2 receptor antagonist (IC 50 values are 16 and > 30,000 nM for CCK 2 and CCK 1 respectively). Displays anxiolytic and antipsychotic properties in vivo . | [in vivo]
LY288513 (3, 10 mg/kg, i.p.; 10, 30 mg/kg, p.o.) produces an anxiolytic-like action in mice[3].
LY288513 (1000 mg/kg, p.o.) potentiates the effects of a CNS depressant, slightly lowered body temperature, and had modest sedative effects only at the highest dose examined[3]. | Animal Model: | Male CD-l mice[3] | | Dosage: | 3, 10 mg/kg; 10, 30 mg/kg | | Administration: | I.p.; p.o. | | Result: | Displayed anxiolytic-like effects in the elevated plusmaze.
|
| [storage]
Store at -20°C |
|
|